文献速递湿疹皮炎与荨麻疹

外用系统糖皮质激素治疗特应性皮炎的安全性与疗效系统综述

A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis.
PubMed 文献 · J Am Acad Dermatol · 2017-12-06

该系统综述检索多个数据库,纳入52篇综述和12项研究,评估系统糖皮质激素(口服、肌注、静脉)治疗各年龄段特应性皮炎的安全性与疗效。文献普遍共识为仅限短期使用作为过渡至保糖皮质激素治疗,系统副作用涉及生长抑制、骨质疏松、肾上腺功能不全等多种不良反应,证据不足以确定最佳给药方式或疗程。

要点

  • 系统糖皮质激素治疗特应性皮炎应限于短期使用,作为过渡至保糖皮质激素治疗的桥梁。
  • 系统副作用包括儿童生长抑制、骨质疏松、肾上腺功能不全、库欣综合征、高血压、糖尿病等。
  • 现有证据不足以确定系统糖皮质激素治疗特应性皮炎的最佳给药方式或疗程。

核心结论

  • 证据不足以确定特应性皮炎系统糖皮质激素的最佳给药方式或疗程。
  • 文献普遍共识为将系统糖皮质激素使用限制于短期疗程,作为过渡至保糖皮质激素治疗的桥梁。

研究设计与样本

  • 系统综述检索PubMed、Embase、Medline、Scopus、Web of Science和Cochrane Library。
  • 纳入52篇综述(系统综述、指南、治疗综述)和12项研究,对象为各年龄段确诊特应性皮炎患者。

主要发现

  • 系统糖皮质激素的系统副作用包括儿童生长抑制、骨质疏松、骨坏死、肾上腺功能不全、库欣综合征、高血压、糖耐量异常、糖尿病、胃炎、胃食管反流、消化性溃疡病、体重增加、情绪不稳、行为改变、机会性感染、白内障、青光眼、肌病、肌痛、感觉异常、假性脑瘤、高脂血症、恶性肿瘤、血栓形成、皮肤萎缩、睡眠障碍和反跳性发作。

临床怎么用

  • 临床使用系统糖皮质激素治疗特应性皮炎时,应限于短期疗程并作为过渡至保糖皮质激素治疗的桥梁。

局限性

  • 各研究对基线临床严重度、糖皮质激素给药方式和剂量、治疗反应报告不完整且异质性大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic corticosteroids are often used to treat atopic dermatitis (AD). However, few studies have assessed the safety and efficacy of systemic corticosteroids in AD. OBJECTIVE: To systematically review the literature on efficacy and safety of systemic corticosteroid use (oral, intramuscular, and intravenous) in AD. METHODS: PubMed, Embase, Medline, Scopus, Web of Science, and Cochrane Library were searched. We included systematic reviews, guidelines, and treatment reviews of systemic corticosteroid use among patients of all ages with a diagnosis of AD (52 reviews and 12 studies). RESULTS: There was general consensus in the literature to limit the use of systemic steroids to short courses as a bridge to steroid-sparing therapies. Systemic side effects include growth suppression in children, osteoporosis, osteonecrosis, adrenal insufficiency, Cushing syndrome, hypertension, glucose intolerance, diabetes, gastritis, gastroesophageal reflux, peptic ulcer disease, weight gain, emotional lability, behavioral changes, opportunistic infections, cataracts, glaucoma, myopathy, myalgia, dysaesthesia, pseudotumor cerebri, hyperlipidemia, malignancy, thrombosis, skin atrophy, sleep disturbance, and rebound flaring. LIMITATIONS: Baseline clinical severity, corticosteroid delivery and dose, and treatment response were reported incompletely and heterogeneously across studies. CONCLUSIONS: Evidence is not strong enough to determine optimal delivery or duration of systemic corticosteroids in AD.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Yu SH, Drucker AM, Lebwohl M, et al. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2017. PMID: 29032119. doi:10.1016/j.jaad.2017.09.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。